Endometrial cancer drug cuts progression or death risk 41%

• by Mouj Hijazi

• October 27, 2026

Risk of Injury Among Children and Youths Whose Mothers Experienced Violent Injury: A Systematic Review and

• by Marissa Fazio, Barbara Haas, Sarah Bahreinian, Sorina Andrei, Hilary K. Brown, Tharani Raveendran, Natasha Saunders

• September 11, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

• by Kathryn Wighton

• June 26, 2026

• 3 min

Cost Analysis and Resource Utilization of Gynecologic Cancer-Related Thoracenteses and Paracenteses

• by Yingao Zhang, Olivia Foy, Grace Pipes, Margaret I. Liang

• July 21, 2026